Literature DB >> 19010710

Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.

Gianluigi Lunardi1, Salvatore Galati, Domenicantonio Tropepi, Vincenzo Moschella, Livia Brusa, Mariangela Pierantozzi, Alessandro Stefani, Silvia Rossi, Francesco Fornai, Ernesto Fedele, Paolo Stanzione, Atticus H Hainsworth, Antonio Pisani.   

Abstract

To assess possible differences in dopamine metabolism that could parallel disease progression in Parkinson's disease (PD), we measured dopamine (DA) and its metabolites in the cerebrospinal fluid (CSF) in PD patients at different stages of disease: de novo (DEN), advanced not showing dyskinesias (ADV), and advanced with dyskinesias (DYS). DA, homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) were significantly higher in DEN patients compared with other groups. A negative exponential correlation related DA level and disease duration. The HVA/DA ratio was significantly higher in the ADV and DYS group than that found in DEN group. Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization. On the contrary, a late change in DA turnover (increased HVA/DA ratio) is documented in patients with longer disease duration. Our results suggest that the appearance of dyskinesia may not be related to a further loss of DA terminals but to a different, abnormal, DA turnover.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010710     DOI: 10.1016/j.parkreldis.2008.10.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

2.  Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Authors:  L Brusa; A Orlacchio; A Stefani; S Galati; M Pierantozzi; C Iani; N B Mercuri
Journal:  Funct Neurol       Date:  2013 Apr-May

3.  Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.

Authors:  Nina Nevalainen; Sara Af Bjerkén; Martin Lundblad; Greg A Gerhardt; Ingrid Strömberg
Journal:  J Neurochem       Date:  2011-05-25       Impact factor: 5.372

4.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

5.  Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.

Authors:  Gian Pal; Bichun Ouyang; Leo Verhagen; Geidy Serrano; Holly A Shill; Charles H Adler; Thomas G Beach; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2018-01-30       Impact factor: 10.338

6.  Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.

Authors:  Freja H Hansen; Tina Skjørringe; Saiqa Yasmeen; Natascha V Arends; Michelle A Sahai; Kevin Erreger; Thorvald F Andreassen; Marion Holy; Peter J Hamilton; Viruna Neergheen; Merete Karlsborg; Amy H Newman; Simon Pope; Simon J R Heales; Lars Friberg; Ian Law; Lars H Pinborg; Harald H Sitte; Claus Loland; Lei Shi; Harel Weinstein; Aurelio Galli; Lena E Hjermind; Lisbeth B Møller; Ulrik Gether
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

7.  Bridging molecular genetics and biomarkers in lewy body and related disorders.

Authors:  Gilbert J Ho; Willie Liang; Masaaki Waragai; Kazunari Sekiyama; Eliezer Masliah; Makoto Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2011-07-03

8.  Intranasal LPS-mediated Parkinson's model challenges the pathogenesis of nasal cavity and environmental toxins.

Authors:  Qing He; Wenbo Yu; Jianjun Wu; Chan Chen; Zhiyin Lou; Qiong Zhang; Jian Zhao; Jian Wang; Baoguo Xiao
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

9.  Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart.

Authors:  Enrica Olivola; Mariangela Pierantozzi; Paola Imbriani; Claudio Liguori; Mario Stampanoni Bassi; Marco Conti; Vincenza D'Angelo; Nicola Biagio Mercuri; Alessandro Stefani
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

Review 10.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.